Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Petty

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
American Journal of Obstetrics and Gynecology|October 1, 1993
Stuck twin syndrome: outcome in thirty-seven consecutive casesD P Reisner, B S Mahony, C N Petty, et al.
Leukemia|August 26, 2014
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myelomaS Z Usmani, Q Zhang, K Stratton, et al.
Leukemia|April 18, 2012
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocolsS Z Usmani, B Nair, P Qu, et al.
Blood Cancer Journal|July 30, 2016
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myelomaY Jethava, A Mitchell, M Zangari, et al.
Blood Cancer Journal|September 17, 2016
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myelomaY Jethava, A Mitchell, M Zangari, et al.
Blood Cancer Journal|February 25, 2017
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic markerS S Chavan, J He, R Tytarenko, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
American Journal of Obstetrics and Gynecology|October 1, 1993
Stuck twin syndrome: outcome in thirty-seven consecutive casesD P Reisner, B S Mahony, C N Petty, et al.
Leukemia|August 26, 2014
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myelomaS Z Usmani, Q Zhang, K Stratton, et al.
Leukemia|April 18, 2012
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocolsS Z Usmani, B Nair, P Qu, et al.
Blood Cancer Journal|July 30, 2016
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myelomaY Jethava, A Mitchell, M Zangari, et al.
Blood Cancer Journal|September 17, 2016
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myelomaY Jethava, A Mitchell, M Zangari, et al.
Blood Cancer Journal|February 25, 2017
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic markerS S Chavan, J He, R Tytarenko, et al.
Pageof 2